Safety and Efficacy of SA09012 in Asthma

NCT ID: NCT01740986

Last Updated: 2015-11-16

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

225 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-11-30

Study Completion Date

2015-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Clinical Study to Evaluate the Efficacy, Dose-response and Safety of SA09012 in Bronchial Asthma Patients

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Mild to Moderate Bronchial Asthma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Caregivers Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

SA09012 Low dose

Group Type EXPERIMENTAL

SA09012 Low dose

Intervention Type DRUG

Tablet, b.i.d

SA09012 High dose

Group Type EXPERIMENTAL

SA09012 High dose

Intervention Type DRUG

Tablet, b.i.d

Placebo

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Tablet, b.i.d

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

SA09012 Low dose

Tablet, b.i.d

Intervention Type DRUG

SA09012 High dose

Tablet, b.i.d

Intervention Type DRUG

Placebo

Tablet, b.i.d

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Diagnosis or presence of asthma within 3 months of the prestudy visit

1. Increase in PEF ≥ 20% or ≥ 60L/min from baseline value after taking Bronchodilator at screening or within the 3 months of the prestudy visit
2. Increase in FEV1 ≥ 12% and ≥ 200mL from baseline value after taking Bronchodilator at screening or within the 3 months of the prestudy visit
* FEV1 or PEF between 60% and 85% of the predicted value at screening or within the 3 months of the prestudy visit
* Having signed an informed consent

Exclusion Criteria

* Patient who has severe asthma
* Patient with an AST or ALT \> 2x ULN (upper limit of normal) in the screening visit
* Patient with more than 10 pack year of cigarettes history
Minimum Eligible Age

20 Years

Maximum Eligible Age

79 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

SamA Pharmaceutical Co., Ltd

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Young Kyoon Kim, MD

Role: PRINCIPAL_INVESTIGATOR

Seoul ST. Mary's Hospital The Catholic University of Korea

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Chonbuk National University Hospital

Chonbuk, , South Korea

Site Status

Chonnam National University Hospital

Gwangju, , South Korea

Site Status

Ajou University Hospital

Gyeonggi-do, , South Korea

Site Status

Bucheon St. Mary's Hospital, The Catholic University of Korea

Gyeonggi-do, , South Korea

Site Status

Hallym University Sacred Heart Hospital

Gyeonggi-do, , South Korea

Site Status

Soon Chun Hyang University Bucheon Hospital

Gyeonggi-do, , South Korea

Site Status

Chungbuk National University Hospital

Jungbuk, , South Korea

Site Status

Konkuk University Medical Center

Seoul, , South Korea

Site Status

Korea University Guro Hospital

Seoul, , South Korea

Site Status

KyungHee University Medical Center

Seoul, , South Korea

Site Status

Seoul St. Mary's Hospital, The Catholic University of Korea

Seoul, , South Korea

Site Status

Soonchunhyang University Hospital, Seoul

Seoul, , South Korea

Site Status

St. Paul's Hospital, The Catholic University of Korea

Seoul, , South Korea

Site Status

Yonsei University, Gangnam Severance Hospital

Seoul, , South Korea

Site Status

Countries

Review the countries where the study has at least one active or historical site.

South Korea

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

SA09012-P2

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Study in Mild Asthmatic Patients
NCT00748306 COMPLETED PHASE2
Safety and Efficacy of WIN-901X in Asthma
NCT01820481 COMPLETED PHASE2